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Summary
Patients with chronic heart failure who are not eligible for
heart transplant and whose life expectancy depends mainly
on the heart disease may benefit from mechanical circu-
latory support. Mechanical circulatory support restores ad-
equate cardiac output and organ perfusion and eventually
improves patients’ clinical condition, quality of life and
life expectancy. This treatment is called destination therapy
(DT) and we estimate that in Switzerland more than 120
patients per year could benefit from it. In the last 10 years,
design of the devices, implantation techniques and pro-
gnoses have changed dramatically. The key to successful
therapy with a left ventricular assist device is appropriate
patient selection, although we are still working on the
definition of reliable inclusion and exclusion criteria and
optimal timing for surgical implantation.
Devices providing best long-term results are continuous
flow, rotary or axial blood pumps implanted using min-
imally invasive techniques on a beating heart. These new
devices (Thoratec HeartMate II and HeartWare HVAD)
have only a single moving part, and have improved durab-
ility with virtually 10 years freedom from mechanical fail-
ure. In selected patients, the overall actuarial survival of
DT patients is 75% at 1 year and 62% at 2 years, with a
clear improvement in quality of life compared with med-
ical management only. Complications include bleeding and
infections; their overall incidence is significantly lower
than with previous devices and their management is well
defined. DT is evolving into an effective and reasonably
cost-effective treatment option for a growing population of
patients not eligible for heart transplant, showing encour-
aging survival rates at 2 years and providing clear improve-
ment in quality of life. The future is bright for people suf-
fering from chronic heart failure.
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The need
“Mechanical problems need mechanical solutions” sum-
marises well our 10 years of experience in the management
of heart failure patients. When even the most advanced
pharmacological therapy fails to achieve adequate organ
perfusion in patients with chronic heart failure (CHF) with
reduced ejection fraction, the only effective solution is
mechanical circulatory support (MCS) [1].
MCS clearly provides better haemodynamic support com-
pared with pharmacological treatment, restoring adequate
organ perfusion and preventing organ dysfunction [1–3]. In
patients with CHF who are not candidate for heart trans-
plant (HTx), or are candidates but have a low chance of get-
ting an organ and whose life expectancy depends mainly on
the heart disease, MCS treatment could become lifelong,
hence the name “destination therapy” (DT). The efficacy
of DT compared with other combined medical treatments
in patients with end-stage heart failure ineligible for trans-
plantation was demonstrated for the first time in the
REMATCH trial, back in 2001 [1]. In 2003, MCS therapy
was expanded to include the intent of long-term therapy in
patients not eligible for HTx, introducing the concept of
DT [2]. Since then, several trials involving different types
of left ventricular assist devices (LVADs) have supported
the clinical benefits of MCS for the treatment of patients
deemed unsuitable for HTx [3].
The majority of heart transplant centres consider as con-
traindications to HTx age above 70 years, fixed pulmonary
hypertension with a transpulmonary gradient of above 15
mm Hg and vascular resistance above 6 Wood units, history
of recent cancer disease or any other comorbidity reducing
life expectancy despite HTx [4]. Moreover, there are can-
didates for HTx who have a small chance of being trans-
planted because of their morphology or blood group, and a
shortage of donors.
The number of HTx worldwide has reached a plateau at
4500 per year [5], while potential candidates for DT ther-
apy are increasing. The number of patients who could po-
tentially benefit from DT per year in Switzerland is estim-
ated at 120. In a nationwide survey in 2005, the incidence
of heart failure in our country was 64.9 per 100000 adult
inhabitants [6], with a clear predominance in the group
aged 55–85 years. It is estimated that the number of people
>65 years of age will double in the next 20 to 30 years [5,
7] and CHF may affect nearly 10% of people >65 years of
age [5].
In 2005 in Switzerland, there were 63 patients on the wait-
ing list for HTx and 33 were transplanted. In 2014, the
number of patients on the waiting list for HTx had in-
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creased by 100% (124 patients), but the number of patients
transplanted had not increased accordingly since only 36
received an organ. This growth in the number of CHF pa-
tients is probably a result of the reduction in death from
myocardial infarction thanks to improvements in coronary
revascularisation treatments and implantation of cardiac
defibrillators and resynchronisation therapy.
Because of the organ shortage and the rapid progression
of heart failure despite optimal medical treatment, a con-
siderable number of patients pass away while waiting for
an organ. In the Swisstransplant 2015 annual report, the
mortality rate of patients listed for HTx during the period
2010–2014 was 6.5%.
Based on these epidemiological data, we could speculate
that in our country, about 120 patients per year could be-
nefit from a LVAD as DT. From January 2015, this therapy
has a specific reimbursement code (SwissDRG version
5.0), even if consumables such as battery packages and
technical controls are not reimbursed yet. However, in our
country, DT will probably be generally accepted as one of
the treatment options only if a national cost-effective ana-
lysis related to the Swiss healthcare system were to clearly
prove its benefit.
The right candidate
The key of successful therapy with a LVAD is appropriate
patient selection, but most of the patient selection criteria
are broad, and are based on clinical experience of single
centres and data collected by multi-institutional registries.
Moreover, almost all the parameters considered as selec-
tion criteria change over time owing to fluctuation of organ
function, making the selection criteria dynamic. The risk/
benefit evaluation is an iterative process that is affected
by even small changes in the patient’s physical condition.
The first step in patient selection is the assessment of dis-
ease severity based on clinical status, inotrope dependence
and invasive haemodynamic parameters, followed by oper-
ative risk estimation. Ultimately, confirmation of adequate
psychosocial support and capacity for self-care is also cru-
cial for successful surgery in the long run [8] (table 1). With
worsening clinical status, the need for LVAD increases, but
so does the perioperative risk and optimal operative timing
becomes difficult.
Comorbidity limiting the patient’s survival to less than 2
years, such as an advanced malignancy, severe liver disease
(particularly if cirrhotic), severe lung disease or a severe
neurological or neuromuscular disorder, should be viewed
as a major contraindication to DT.
Another key point for success is to choose the best time
to implant the LVAD and this is still an open issue. Based
on the first poor results, many clinicians implanted left
ventricular support only when patients were severely ill.
But longer durability and fewer complications with modern
devices, as well as recognition of the unpredictability of
heart failure deterioration, has led to a shift toward less
catastrophically ill patients. In our experience, up to 30% of
stable patients listed for HTx deteriorate far enough to re-
quire high-urgency HTx or emergency LVAD and we now
propose earlier implantation, before right-ventricular and
multiorgan failure. It is well documented that patients with
INTERMACS categories above 3 have the best outcome
[2]. INTERMACS is a US registry acquiring data on pa-
tients supported with MCS devices approved by the US
Food and Drug Administration (FDA). INTERMACS clin-
ical profiles are illustrated in table 2. Patients receiving a
durable MCS at INTERMACS patient profile 1 or 2 have
a postoperative mortality that is 44% greater than that of
those receiving a long-term MCS at INTERMACS patient
profile 3 or 4 [9]. However, we should remember that these
levels and their corresponding prognosis have not been
tested or validated in actual patient sets but are helpful for
overall clinical assessment.
As recently outlined by Kirklin et al., DT candidates are
older than candidates to bridge to transplant (mean age 61.7
vs 52.7 years) and have significantly worse multimorbidity
[10]. Although age by itself should not be considered as an
absolute contraindication to DT, older patients often have
more coexisting morbidities and thus are more vulnerable
to complications.
Seventeen percent of DT recipients achieve improvement
or resolution of contraindications to transplantation during
MCS and ultimately receive a HTx and one third of bridge
to transplant patients became noncandidates for transplant-
ation [11].
The clinical experience of the surgeon still plays a major
role in choosing the right moment to implant the pump
because it helps to consider the patient’s frailty. Frailty is
impairment in multiple, interrelated organ systems causing
a decreased homeostatic reserve and increased vulnerabil-
ity to stress [12].
LVAD implantation is still associated with high perioper-
ative mortality: in our experience over the last 5 years the
30-day mortality was 18% (7 patients out of 38, all as
bridge to transplant) and morbidity and costs were consid-
erable as well. However, 80% of our patients had repeated
hospitalisations and were inotrope dependent at the time of
ventricular assist device implantation.
There are several clinical scores created to predict long-
term survival after LVAD implantation, the most used be-
ing the Lietz-Miller score analysing 45 baseline parameters
(laboratory, haemodynamic and clinical) to stratify patients
into low, medium and high risk. However, all the existing
risk models have several important limitations. They are
based on data from patients who underwent implantation of
pulsatile LVADs and the risk models have not yet been val-
idated with continuous-flow devices. Comorbidities such
as diabetes, severe cachexia or obesity were under-repres-
ented but could affect long-term results. There is a clear
and immediate need for more prospective models to define
the timing of and risk associated with LVAD implantation.
Physicians also have to take into account psychosocial and
behavioural issues before including the patient in a DT pro-
gramme and adherence to a complicated heart-failure med-
ical regimen predicts success. The candidate should be able
to self-care the driveline exit site, to handle the maintain-
ing/alternating power source, and to know the emergency
procedures in the case of device alarms.
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Clinical challenges
Right ventricular failure
In our experience, all patients with in end-stage heart fail-
ure have moderate pulmonary artery hypertension and
some degree of right ventricular dysfunction. Predicting the
residual function of the right ventricle after LVAD implant
is a real challenge. As a result of its different anatomy and
embryological origin, the right ventricle has a completely
different functional reserve compared with the left vent-
ricle and works in on-off mode: it works, providing good
left ventricular filling, or it fails completely. There is noth-
ing in between. Left ventricle unloading, and reduction in
left ventricular filling pressure and pulmonary vascular res-
istance often induce an improvement in right ventricular
function after LVAD, but in the early postoperative period
complex mechanisms may contribute to right ventricular
failure. These include a sudden increase in cardiac output,
leading to increased venous return and thus right ventricu-
lar preload, septal shift causing increased right ventricular
wall stress and increased pulmonary vasoreactivity in the
setting of cardiopulmonary bypass, blood transfusions and
inflammation leading to increased right ventricular after-
load. Right ventricular failure after LVAD implantation is
a serious complication, leading to an estimated 19 to 43%
increase in operative mortality and decreased survival [13].
There is no general consensus on the parameters predicting
right ventricular failure and all existing scores have low re-
liability. However, in our experience, right atrial pressure
above 20 mm Hg, mean pulmonary artery pressure below
25 mm Hg, and a large and hypokinetic right ventricle
(>200 ml) are all poor prognostics for isolated left ventricu-
lar support. The risk of developing right ventricular failure
is clearly associated with the underlying disease: it is more
likely to occur in dilated idiopathic than ischaemic cardi-
omyopathy. Also, the rapid unloading of the left ventricle
due to the LVAD can cause left displacement of the inter-
ventricular septum, eventually worsening right ventricular
function. Therefore, pump speed has to be adapted to left
ventricular unloading in the early days after LVAD implant.
Peroperative management that includes possible tricuspid
annuloplasty for moderate to severe tricuspid regurgitation
[14] and the use of selective pulmonary vasodilators (nitric
oxide, prostanoids or type 5 phosphodiesterase inhibitors)
may attenuate the development of early right ventricular
failure [15]. However, interpretation of scientific data is
difficult because most publications identified only univari-
ate predictors and describe mostly first-generation devices.
In critical situations, the use of temporary circulatory sup-
port for the right ventricle, such as extracorporeal mem-
brane oxygenation with a centrifugal pump and cannulas
inserted into the femoral vein and pulmonary artery, may
act as bridge to recovery for the right ventricle, but there
are limited prospective data on evidence of its efficacy.
Pulmonary arterial hypertension with an elevated pulmon-
ary vascular resistance (above 5 Wood units) was once
thought to predict right ventricular failure after LVAD be-
cause these factors are associated with poor outcome after
heart transplantation. More recent studies suggest that de-
pressed right ventricular myocardial function is more ac-
curately characterised by a low right ventricle stroke work
index, low pulmonary arterial pressure and elevated right
atrial pressure. Thus, pulmonary hypertension should not
be considered an absolute contraindication to DT [16, 17].
In our limited experience, the capacity of the right ventricle
to generate high pressure and flow is a favourable pro-
gnostic factor, whereas high central venous pressure and
severe tricuspid regurgitation are detrimental. The impact
of long-term LVAD support on right ventricular function
and on the intrinsic progression of right ventricular dys-
function needs to be investigated and could be a barrier to
the wide acceptance of the DT.
Aortic valve disorders
Because of the possible development of a closed loop of
LVAD flow (blood recirculates from aorta to the left vent-
ricle with poor organ perfusion), patients with more than
mild aortic valve regurgitation need correction of the re-
Table 1: Adapted from American Heart Association recommendation for long-term mechanical circulatory support [8].
DT is beneficial for patients with advanced HF, high 1-year mortality resulting from HF, and the absence of other life-limiting organ dysfunction;
who are failing medical, surgical, and/or device therapies; and who are ineligible for heart transplant.
Class I
Level of Evidence B
Elective rather than urgent implantation of DT can be beneficial when performed after optimisation of medical therapy in advanced HF patients
who are failing medical, surgical, and/or device therapies.
Class IIa
Level of Evidence C
Patients who are ineligible for heart transplantation because of pulmonary hypertension related to HF alone should be considered for bridge to
potential transplant eligibility with durable, long-term MCS
Class IIa
Level of Evidence B
DT is not recommended in patients with advanced kidney disease in whom renal function is unlikely to recover despite improved haemodynamics
and who are therefore at high risk for progression to renal replacement therapy.
Class III
Level of Evidence C
Assessment of nutritional status is recommended as part of the evaluation for patient selection for DT. Class I
Level of Evidence B
Assessment of psychosocial, behavioural, and environmental factors is beneficial as part of the evaluation for patient selection for durable, long-
term MCS.
Class I
Level of Evidence C
DT = destination therapy; HF = heart failure; MCS = mechanical circulatory support
Table 2: INTERMACS classes and optimal timing for mechanical circulatory support. Data from: Kirklin JK, et al. Sixth INTERMACS annual report: A 10 000-patient
database. J Heart Lung Transplant. 2014;33:555–64 (table 7) [25].
HF severity
NYHA class
III IIIB IV
INTERMACS profiles 7 6 5 4 3 2 1
VAD implants % 1 1.4 3 14.6 29.9 36.4 14.3
Acceptance None Limited adoption Growing
NYHA = New York Heart Association; VAD = ventricular assist device
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gurgitation concomitant to LVAD implantation. Among the
different surgical options, the primary closure of the aortic
valve using pericardial pledgets (modified Park’s stitch) or
complete closure of the ventricular aortic junction with a
circular patch, seem to be the most effective techniques,
which avoid late thromboembolic complications and recur-
rence of aortic regurgitation in DT patients [18]. However,
the primary closure of the aortic valve precludes any recov-
ery of the left ventricle and rarely induces coronary embol-
ism due to blood stagnation in the aortic root. Mechanical
or biological prosthesis have shown poor long-term results
due to leaflet blockage (mechanical) or stiffening (biolo-
gical), and consequent cerebral embolism due to thrombus
formation [18]. The risk of cerebral embolism will prob-
ably decrease with the introduction of a pump activation al-
gorithm allowing the left ventricle to eject two to six times
per minute and making biological aortic valve replacement
the best treatment for aortic regurgitation. Even if the aor-
tic valve works properly at the time of LVAD implant, 25
to 52% of patients with a continuous-flow pump develop
aortic regurgitation at 1 year owing to the progressive stiff-
ness and fusion of the aortic valve leaflets [19]. Handling
of this situation is difficult and could require surgical cor-
rection. In order to prevent aortic regurgitation developing,
it is reasonable to consider a device-management strategy
that promotes the opening of the aortic valve, as recently
shown by Inamura et al. [20]. However, randomised data
that clearly support the benefits of such a practice are lack-
ing.
Device technology and surgical aspects
The largest international registry on ventricular assist
device therapy started in 2006 during the era in which only
pulsatile pumps were implanted. These devices had several
limitations such as large volume requirements and import-
ant surgical trauma, and were prone to device malfunction
with the need for reoperation within the first 12 months.
Therefore, long-term results were unpromising.
Figure 1
The HeartWare (HeartWare Corporation, Framingham,
Massachussetts, USA) device (HVAD) is a centrifugal, continuous
flow pump with a wide-blade impeller that is magnetically and
hydrodynamically suspended. HVAD pump flow is preload
dependent and afterload sensitive with a speed range of
1800–4000 RPM and a maximum outflow of 10 l/min. HVAD weight
is 160 g and it fits in a hand.
The concept of continuous flow pumps was developed in
1988 with the support of NASA engineers and the first hu-
man implant of the Micro Med DeBakey Noon ventricular
device was in Germany 10 years later [21]. During the last
decade, improvements in pump design resulted in a new
generation of LVADs consisting of small, continuous flow,
rotary and axial blood pumps that are more reliable and
durable. Many devices have been designed and implanted,
but only the two illustrated in figures 1 and 2 have shown
excellent clinical results and currently cover 80% of world-
wide implants.
The continuous flow is generated by a rotor spinning on
an axis parallel to blood flow, a so-called axial pump
(HeartMate II; Thoratec Corp, Pleasanton, CA), or by a ro-
tor revolving in a bell-like chamber conveying blood by
means of centrifugal force (HeartWare HVAD; Heartware
Corp, Framingham, MA). Because the flow is continuous
there is no need for valves or compensating chambers.
Axial and centrifugal pumps both need an inflow cannula
placed into the apex of the left ventricle, an outflow can-
nula sutured to the ascending aorta and a cable piercing the
skin for the energy supply. The axial pump produces the
same flow as the centrifugal pump at a similar mean pres-
sure of 100 mm Hg, but left ventricular unloading is lower.
They both need anticoagulation and antiplatelet treatment
in order to reduce thrombus formation. The HVAD is signi-
ficantly smaller than the HeartMate II and its design better
fits the minimal invasive approach. However, the rationale
behind device selection depends on the surgeon’s experi-
ence in implanting either of them since each system has
its pitfalls to avoid and, at least in Switzerland, implant-
ing institutions still have too low a case load to implant all
devices successfully.
The safest surgical technique requires the establishment of
cardiopulmonary bypass, usually through femoral vessels
when the minimal invasive approach is chosen. However,
some authors propose LVAD implantation without cardiop-
ulmonary bypass even if the procedure is more challenging
for the surgeon and more dangerous for the patient [22].
Schmitto first described the minimal invasive approach that
gives excellent exposure of the cardiac apex through a left
Figure 2
The HeartMate II (Thoratec Corporation, Pleasanton, California,
USA) is a continuous flow axial pump with a magnetically activated
impeller. It weighs 400 g and provides up to 10 l/min flow. It is the
only ventricular assist device for destination therapy approved by
the US Food and Drugs Administration.
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anterolateral thoracotomy, associated with mini-upper ster-
notomy or anterior right thoracotomy for the placement
of the outflow cannula (fig. 3) [23]. The new generation
devices (HeartMate III and MVAD) are significantly smal-
ler than the former generations and will perfectly match the
minimal invasive approach (fig. 4) [24].
Worldwide, here are over 6000 implants of continuous
flow LVADs annually, and over 40% are implanted for DT
[25]. The support time has progressively increased to an
average length of 3 years, with individual cases exceeding
8 years [25, 26].
Outcomes after left ventricular assist device placement
Outcomes after LVAD placement depend on the era of im-
plant, surgical experience and patient characteristics. The
perioperative phase is crucial, with the vast majority of
deaths occurring prior to hospital discharge and associated
with multiorgan failure, bleeding and acute right ventricu-
lar failure [25, 26]. With more patients on long-term con-
tinuous flow LVAD support, the research focus has shifted
Figure 3
Surgical technique: the minimal invasive approach. Patient’s head
is on the right hand side. Left anterior thoracothomy to expose
cardiac apex and insert the inflow cannula (A), the mini right
anterior thoracotomy to expose the ascending aorta to suture the
outflow graft (B) and the point where the driveline pierces the skin
(C).
Figure 4
The MVAD (HeartWare Corporation; Framingham, Massachussetts,
USA). New generation devices are significantly smaller and lighter
than previous generations. They have the possibility to adapt the
orientation of the inflow cannula after the insertion to reduce the
risk of inflow cannula mis-positioning. From: Cheung A,
Chorpenning K, Tamez D, Shambaugh C Jr, Dierlam AEet al.
Design concepts and preclinical results of a miniaturized HeartWare
platform: The MVAD system. Innovations (Phila). 2015;10(3):151-6.
from survival to morbidity, quality of life and a better com-
prehension of the altered physiology induced by continu-
ous flow.
Improvements in DT outcomes have come primarily from
advances in device technology and not from changes in pa-
tient selection. The evolution from pulsatile to continuous-
flow pumps has dramatically improved survival [2]. The
sixth INTERMACS report showed that, from a total of
10542 MCS implantations, nearly half of the patients from
2011–2013 (41%) received an LVAD as DT [25]. During
the year 2011, 96% of devices implanted were continuous-
flow pumps and DT, which accounted for 38% of implants,
involved only continuous-flow devices [2]. These new
pumps represent a milestone for LVAD therapy, providing
much better patient outcomes. The overall actuarial surviv-
al among all DT patients was 75% at 1 year and 62% at 2
years, with a freedom from device exchange of 94% at 24
months compared with 51% for pulsatile pumps [2].
In another multicentre study involving 200 transplantation-
ineligible patients who received the HeartMate II, the sur-
vival rate was 68% at 1 year and 58% at 2 years [13]. Com-
pared with the medical management arm of the REMATCH
trial, in which survival was 25% (1 year) and 8% (2 years),
the survival benefit of DT appears evident [26].
More recently, the ADVANCE trial has reported 90% sur-
vival at 12 months as a bridge to transplantation [27].
A single-centre study demonstrated an almost 3-fold im-
provement in survival after durable MCS for profile 3 and
4 patients compared with profile 1 and 2 patients (p =
0.05) [28] Profile 6 or 7 patients, who by definition have
advanced New York Heart Association (NYHA) class III
symptoms, are, in general, considered too well for MCS on
the basis of current data. However, a clinical trial is now
underway to investigate MCS in this group [29].
Managing the complications
Continuous flow pumps are not immune to complications,
and are associated with specific clinical problems including
gastrointestinal bleeding, acquired von Willebrand disease,
arteriovenous malformations, haemolysis, pump thrombos-
is and aortic regurgitation.
Bleeding
Bleeding problems have become more prominent than
strokes with the latest devices and occur in 20 to 40%
of patients in the first 12 months after implant [30–32].
The propensity for bleeding in patients supported by
continuous-flow devices may be driven by acquisition of
a von Willebrand syndrome because of the effect of shear
forces on the von Willebrand multimer [30]. The molecule
is composed of four polymers and continuous flow induces
the malformation of multimer 4 rendering the patient co-
agulopathic. All patients develop this acquired deficiency
within a month or two of pump implantation [31]. The
bleeding is typically manifest as mucosal bleeding ob-
served primarily from arteriovenous malformations in the
gastrointestinal tract.
There is speculation that the decrease in arterial pulsatility
contributes to these complications, even though the patho-
physiology is still unclear [33]. The latest generation of
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continuous-flow pumps takes into account the pulsatility
issue, although it is still unknown how much pulsatility is
sufficient to normalise vascular response avoiding specific
complications. The Heartware HVAD has developed a spe-
cific algorithm of pump activation called “Lavare cycle”
that allows intermittent aortic valve opening for washing
the aortic root [34], even if the systemic pressure has not
the physiological pulsatile profile. The new HeartMate III,
which is still under investigation, can produce near-
physiological pulsatile pressure of about 25 mm Hg, which
is a considerable step forward towards physiological
pulsatile flow [33]. Almost half of our patients (15 out
of 38) experienced some bleeding complications during
LAVD support, but only one required surgical resection of
bleeding bowel.
Bleeding management includes cessation of anticoagula-
tion and endoscopy with control of bleeding sources.
Rarely, resection of the bleeding area is required. Despite
its high incidence, the bleeding was responsible for death
only in 3% of patients in a long-term study involving the
HeartMate II [25, 33].
Pump thrombosis
Anticoagulation and antiplatelet therapy are necessary to
prevent thrombus formation within the flow path of any or
all of the components that constitute the pump, including
the titanium inflow cannula, the outflow graft and the pump
housing that contains the rotor. The initial recommenda-
tions (FDA study) for the HeartMate II were a prothrombin
time international normalised ratio (INR) of 2 to 3 and a
full dose of acetylsalicylic acid (ASA), later reduced to an
INR of 1.5 and ASA dose 100 mg/day. However this regi-
men has been associated with a higher incidence of pump
thrombosis.
In a recent meta-analysis including 12 studies, Xie et al.
reported an overall weighted incidence of device failure
of 3.9% (range 1–11.3%) at 1 year and 6.5% at 2 years.
Pump thrombosis was the most common cause of device
failure (50.5%), followed by lead or cable damage (21.7%),
mechanical pump failure (11.6%), device-related infection
(11.1%) and surgical complications from implantation
(2.5%) [34]. Thrombus formation within the pump should
be suspected in cases of increased power consumption
without increase in pump flow and isolated lactate dehyd-
rogenase rise above three times the normal value. Echocar-
diography and computed tomography are the most effect-
ive tools to investigate pump thrombosis. If the thrombus
is confirmed, heparin is administered to bring the partial
thromboplastin time to above 50 sec. Persistent haemolys-
is, power spikes and/or heart failure symptoms may be ad-
dressed with more aggressive antithrombotic therapy with
direct thrombin inhibitors, although the only evidence of
the effectiveness of these interventions at this time is an-
ecdotal. If haemolysis persists despite aggressive antith-
rombotic therapy, pump exchange should be considered if
the patient is deemed a surgical candidate. We have had
three patients suffering from this dreadful complication,
two successful received a new pump and one did not sur-
vive thrombolytic agent (tissue plasminogen activator) ad-
ministration.
Driveline infection
The “Achilles heel” of current VADs is the driveline pier-
cing the skin at the level of the abdominal wall (fig. 5). Pa-
tients are given instructions on how to handle the wound
with sterile technique; however, infection of the driveline
is frequent and the longer the implant, the higher is the in-
fection rate. The prevalence rate of driveline infections is
23% at 1 year and 35% at 2 years when the velour coating
is used. The use of silicon coating for the cable piercing the
skin seems effective in reducing the incidence of driveline
infection by 50% [35].
When infection sets in, aggressive antibiotic treatment is
necessary in combination with surgical debridement and
use of vacuum assisted closure dressing in order to avoid
pump infection. The risk that the driveline infection could
spread to the pump is very low. If this dreadful complica-
tion should occur, the pump needs to be changed. This oc-
curs in less than 3% of patients [36]. The surgical proced-
ure is technically demanding and is associated with high
mortality and morbidity rates.
The technology for solving the driveline infection problem
exists and is called transcutaneous energy transfer (TET).
It was first used with the LyonHeart system (Arrows Inc.)
almost 20 years ago. Over time this technology has become
more efficient and reliable and we believe in the near future
all devices will be equipped with TET systems, improving
also patients’ comfort.
The physician in charge of MCS therapy should have a
dedicated profile and we definitely need to create a ded-
icated subspecialty in cardiology and cardiac surgery to
clearly define the profile of the heart failure specialist.
Conclusions
DT is evolving into an effective and reasonably cost-effect-
ive treatment option for the growing population of patients
not eligible for heart transplantation, showing encouraging
survival rates at 2 years and providing clear improvement
in quality of life. The most important predictor of positive
outcome is proper patient selection, which requires com-
prehensive assessment of the indication and contraindica-
tions, risk factors and of right ventricular failure, as well as
optimal surgical timing. As suggested by Miller et al. [37],
we should abandon the approach based on preimplant de-
Figure 5
Driveline pierces the skin. This area is at high infection risk even if
appropriate care is given.
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termination of whether a ventricular assist device for a giv-
en patient is a bridge to transplant or recovery or destina-
tion therapy. In the future, we will establish that a patient
is in need of mechanical circulatory support, based on the
presence of indications and absence of contraindications,
and leave the question of duration of the support open de-
pending on clinical evolution and organ availability. The
clinical results at 5 and 10 years associated with DT could
be so exceptionally good as to prove the noninferiority of
ventricular assist device therapy compared with heart trans-
plantation. The future is bright for people suffering from
chronic heart failure.
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Figures (large format)
Figure 1
The HeartWare (HeartWare Corporation, Framingham, Massachussetts, USA) device (HVAD) is a centrifugal, continuous flow pump with a
wide-blade impeller that is magnetically and hydrodynamically suspended. HVAD pump flow is preload dependent and afterload sensitive with a
speed range of 1800–4000 RPM and a maximum outflow of 10 l/min. HVAD weight is 160 g and it fits in a hand.
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Figure 2
The HeartMate II (Thoratec Corporation, Pleasanton, California, USA) is a continuous flow axial pump with a magnetically activated impeller. It
weighs 400 g and provides up to 10 l/min flow. It is the only ventricular assist device for destination therapy approved by the US Food and Drugs
Administration.
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Figure 3
Surgical technique: the minimal invasive approach. Patient’s head is on the right hand side. Left anterior thoracothomy to expose cardiac apex
and insert the inflow cannula (A), the mini right anterior thoracotomy to expose the ascending aorta to suture the outflow graft (B) and the point
where the driveline pierces the skin (C).
Figure 4
The MVAD (HeartWare Corporation; Framingham, Massachussetts, USA). New generation devices are significantly smaller and lighter than
previous generations. They have the possibility to adapt the orientation of the inflow cannula after the insertion to reduce the risk of inflow
cannula mis-positioning.
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Figure 5
Driveline pierces the skin. This area is at high infection risk even if appropriate care is given.
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